Suppr超能文献

胰腺导管腺癌患者腹水的意义:一项病例对照研究。

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study.

作者信息

Baretti Marina, Pulluri Bhargavi, Tsai Hua-Ling, Blackford Amanda L, Wolfgang Christopher L, Laheru Daniel, Zheng Lei, Herman Joseph, Le Dung T, Narang Amol K, de Jesus-Acosta Ana

机构信息

Department of Medicine, The University of Vermont Medical Center, Burlington, VT.

Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, The Johns Hopkins Biostatistics Center.

出版信息

Pancreas. 2019 Apr;48(4):585-589. doi: 10.1097/MPA.0000000000001262.

Abstract

OBJECTIVE

Limited data exist on the impact of ascites in pancreatic ductal adenocarcinoma (PDAC). We evaluated the survival outcomes of patients with PDAC and ascites.

METHODS

Retrospective, single-institution, case-control study including patients with newly diagnosed PDAC from 2007 to 2016. One hundred fifty-four patients with ascites at diagnosis (case group) and 154 controls were matched on age, sex, stage, Eastern Cooperative Oncology Group performance, surgical treatment, lymph node, and margin status. Ascites was defined as computed tomography-detected fluid in the pelvic/peritoneal cavity. Overall survival was compared between groups via Cox proportional hazards models with a gamma frailty term to account for the correlation between matched pairs on entire cohort and by disease stages for subgroup analysis.

RESULTS

The 154 matched cases included 24 resectable, 19 borderline resectable, 51 locally advanced, and 60 metastatic disease. Patients with ascites had higher risk of death compared with those without (conditional hazard ratio, 1.58; 95% confidence interval, 1.23-2.03; P < 0.001). Stratified analysis showed a significant association between ascites and poor prognosis in patients with localized disease (conditional hazard ratio, 1.62; 95% confidence interval, 1.18-2.24; P = 0.003).

CONCLUSIONS

Radiographic ascites is a poor prognostic factor in PDAC. Our findings may aid physicians in considering systemic therapy prior to attempting local treatments.

摘要

目的

关于腹水对胰腺导管腺癌(PDAC)影响的数据有限。我们评估了PDAC合并腹水患者的生存结局。

方法

一项回顾性、单机构病例对照研究,纳入2007年至2016年新诊断为PDAC的患者。154例诊断时伴有腹水的患者(病例组)与154例对照在年龄、性别、分期、东部肿瘤协作组体能状态、手术治疗、淋巴结及切缘状态方面进行匹配。腹水定义为计算机断层扫描检测到盆腔/腹腔内有液体。通过带有伽马脆弱项的Cox比例风险模型比较两组的总生存期,以考虑整个队列中匹配对之间的相关性,并按疾病分期进行亚组分析。

结果

154例匹配病例包括24例可切除、19例临界可切除、51例局部晚期和60例转移性疾病。与无腹水患者相比,有腹水患者的死亡风险更高(条件风险比,1.58;95%置信区间,1.23 - 2.03;P < 0.001)。分层分析显示,局限性疾病患者中腹水与预后不良之间存在显著关联(条件风险比,1.62;95%置信区间,1.18 - 2.24;P = 0.003)。

结论

影像学检查发现的腹水是PDAC的不良预后因素。我们的研究结果可能有助于医生在尝试局部治疗之前考虑全身治疗。

相似文献

1
The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study.
Pancreas. 2019 Apr;48(4):585-589. doi: 10.1097/MPA.0000000000001262.
3
Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study.
Pancreas. 2014 Mar;43(2):287-90. doi: 10.1097/MPA.0000000000000089.

引用本文的文献

2
Complement pathway activation mediates pancreatic cancer-induced muscle wasting and pathological remodeling.
J Clin Invest. 2025 Apr 8;135(12). doi: 10.1172/JCI178806. eCollection 2025 Jun 16.
4
Cardiac Atrophy, Dysfunction, and Metabolic Impairments: A Cancer-Induced Cardiomyopathy Phenotype.
Am J Pathol. 2024 Oct;194(10):1823-1843. doi: 10.1016/j.ajpath.2024.06.008. Epub 2024 Jul 18.
5
Ascites Is a Poor Prognostic Factor in Advanced Pancreatic Adenocarcinoma and May Be Undertreated: A Prospective Cohort Study.
Clin Transl Gastroenterol. 2024 Jul 1;15(7):e00719. doi: 10.14309/ctg.0000000000000719.
7
Prognostic Impact of Minimal Pelvic Fluid in Locally Advanced Pancreatic Cancer: A Multicenter Retrospective Study.
Turk J Gastroenterol. 2023 Dec;34(12):1249-1256. doi: 10.5152/tjg.2023.23309.
8
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients.
Cancer Res Treat. 2023 Oct;55(4):1077-1086. doi: 10.4143/crt.2022.1630. Epub 2023 Jun 12.
9
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies.
Front Oncol. 2023 Mar 16;13:1138759. doi: 10.3389/fonc.2023.1138759. eCollection 2023.
10
Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.
Front Pharmacol. 2022 Aug 24;13:933457. doi: 10.3389/fphar.2022.933457. eCollection 2022.

本文引用的文献

1
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.
2
Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.
Clin Colorectal Cancer. 2016 Dec;15(4):360-368. doi: 10.1016/j.clcc.2016.04.014. Epub 2016 May 7.
3
Pancreatic cancer with malignant ascites: clinical features and outcomes.
Pancreas. 2015 Apr;44(3):380-5. doi: 10.1097/MPA.0000000000000290.
4
Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.
Tumour Biol. 2014 Apr;35(4):3261-8. doi: 10.1007/s13277-013-1426-3. Epub 2013 Nov 27.
5
Malignant ascites: pathophysiology and treatment.
Int J Clin Oncol. 2013 Feb;18(1):1-9. doi: 10.1007/s10147-012-0396-6. Epub 2012 Mar 31.
6
[Pathogenesis and management of refractory malignant ascites].
Bull Cancer. 2011 Jun;98(6):679-87. doi: 10.1684/bdc.2011.1373.
8
Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA.
Gastrointest Endosc. 2010 Feb;71(2):260-5. doi: 10.1016/j.gie.2009.08.025. Epub 2009 Nov 17.
10
Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
Ann Oncol. 2007 May;18(5):945-9. doi: 10.1093/annonc/mdl499. Epub 2007 Feb 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验